United States · 
What does Sofinnova Investments invest in?
Sofinnova Investments invests most often at Series B and Series A (52% of the rounds on record), in sectors such as Collaboration, Consumer and Education.
Sofinnova Investments highlights
- 01
2 cheques in the last 12 months
- 02
Mostly Series B and Series A: 52% of its rounds
- 03
Sole investor in 9 rounds, median $14M
- 04
28 exits from the portfolio
What they do
No descriptive text about Sofinnova Investments was found in the provided homepage text.From their own website
- Type
- VC firm
- Cheque size
- Not stated
- Stages
- GrowthPre-seedSeedSeries ASeries B
- Sectors
- CollaborationConsumerEducation
- Based in
- Menlo Park, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first161 appearances
- 2026
2 rounds
- Oct
- Jun
- 2025
1 round
- Apr
- 2024
1 round
- Mar
- 2019
4 rounds
- Oct
- May
- Apr
- Apr
- 2018
12 rounds
- Dec
- Nov
- Oct
- Aug
- Jul
- Jul
- Jun
- May
- Apr
- Apr
- Apr
- Jan
- 2017
7 rounds
- Dec
- Nov
- Sept
- Sept
- Mar
- Mar
- Feb
- 2016
1 round
- Nov
- 2015
11 rounds
- Nov
- Oct
- Sept
- Aug
- Aug
- Jul
- Jun
- Apr
- Apr
- Apr
- Mar
- 2014
14 rounds
- Dec
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration13 named
ALAlain Louis AzanShareholderiForm ADV
AFAnand F. MehraManaging Member of the General PartneriFiling they signed
EHEric Helmut DelbridgeDirectoriForm ADV
GKGarheng KongExecutive OfficeriFiling they signed
HNHooman No Middle Name ShahlaviShareholder, Secretary and Chief Legal OfficeriForm ADV
JDJames Dennis BrodyChief Compliance OfficeriForm ADV
JIJames Irvin HealyManaging Member of the General PartneriFiling they signed
LGLars Gosta EkmanBoard of Directors Member, Executive PartneriForm ADV
MMMaha Mehdi KatabiShareholder, Director and Vice PresidentiForm ADV
MFMichael F. PowellManaging Member of the General PartneriFiling they signed
NMNathalie Marie AuberShareholder, Director and Chief Financial OfficeriForm ADV
SBSarah BhagatManaging Member of the GP of the GPiFiling they signed
SFSrinivas F. AkkarajuManaging Member of the General PartneriFiling they signed
We also hold 31 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$5.4Bassets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
- Legal name
- Sofinnova Investments, Inc.
- SEC number
- CRD 160297
Funds on its Form ADV
7 private funds, $2.3B in gross assets · filed Sept 2024
Venture 4Hedge 3
- Sofinnova Venture Partners X, L.P.Venture59 investors$803M
- Sofinnova Bioequities Enhanced Master Fund, L.P.Hedge18 investors$766M
- Sofinnova Venture Partners IX, L.P.Venture52 investors$289M
- Sofinnova Venture Partners XI, L.P.Venture51 investors$236M
- Sofinnova Bioequities Master Fund, LTD.Hedge50 investors$204M
- Sofinnova Venture Partners VIII, L.P.Venture41 investors$7.7M
- Sofinnova Synergy Master Fund, L.P.Hedge13 investors$5.1M
Who backs their funds
2 LPs on record in Sofinnova Investments's funds
- Committed
- $155M
- Funds
- 3
- Vintages
- 2007 to 2014
The institutions that put money into its funds, which the firm then invests in companies.Source: the pension's own report, latest Sept 2025.
- California State Teachers Retirement System2 funds$80M
Fund Vintage Committed Sofinnova Venture Partners IX 2014 $50M Sofinnova Venture Partners VIII 2011 $30M 
Oregon Public Employees Retirement Fund2 funds$75MFund Vintage Committed Sofinnova Venture Partners VIII 2011 $50M Sofinnova Venture Partners VII 2007 $25M
Exits from the portfolio
Companies it backed that were later bought or listed28 in all
ZS PharmaBought by AstraZeneca$2.7BNov 2015
ConteXtreamBought by HP SoftwareUndisclosedMay 2015
Hyperion TherapeuticsBought by Horizon Pharma$1.1BMar 2015
Cortina SystemsBought by INPHI$131MOct 2014
Civitas TherapeuticsBought by Acorda Therapeutics$525MSept 2014
Labrys BiologicsBought by Teva Pharmaceutical Industries$825MJun 2014
Aerie PharmaceuticalsListedUndisclosedOct 2013
Trius TherapeuticsBought by Cubist Pharmaceuticals$707MJul 2013
Trius TherapeuticsListedUndisclosedJul 2013
SARcode BioscienceBought by Shire$160MMar 2013
KaloBios PharmaceuticalsListedUndisclosedJan 2013
NextWave PharmaceuticalsBought by PfizerUndisclosedOct 2012
Laszlo SystemsBought by Critical Path Inc.UndisclosedFeb 2012
IntellikineBought by Takeda Pharmaceutical$310MDec 2011
Vicept TherapeuticsBought by Allergan$275MJul 2011
HeadSproutBought by Newell RubbermaidUndisclosedMar 2011
HelloSoftBought by Imagination Technologies$47MNov 2010
UPEKBought by AuthenTecUndisclosedSept 2010
Anthera PharmaceuticalsListedUndisclosedMar 2010
The latest 20 here. An exit counts when it came after the firm's first round in the company. From historical deal records.